arrow
N

Nicholas A. Kennedy

royal devon university healthcare nhs foundation trust
H指数:61
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn’s disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial

基于磁共振成像的简化MaRIA评分与克罗恩病未来的手术相关,但与回结肠镜炎症的 modest 相关性限制了其在临床试验中的实用性:PROFILE试验结果

2026-05-010
OA
Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease

理解抗TNF治疗失败:预先存在的抗药抗体常见,但无法在体外中和药物活性,也不影响克罗恩病患者对英夫利昔单抗或阿达木单抗的临床反应

2025-10-010
PRE
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
2024-06-0115
OAAI
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
2024-05-0143
OAAI
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib

使用英夫利昔单抗或托法替尼的炎症性肠病患者对流感疫苗的抗体反应减弱

2023-11-062
OAAI
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

炎症性肠病患者在三剂新型冠状病毒肺炎疫苗 (VIP) 后中和针对SARS-CoV-2 Omicron BA.4/5和野生型病毒的抗体反应: 一项前瞻性、多中心、队列研究

2023-10-013
OAAI
Prevalence of NUDT15 Genetic Variants and Incidence of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

炎症性肠病中NUDT15基因变异的患病率和硫嘌呤诱导的白细胞减少症的发生率: 系统回顾和荟萃分析

2023-06-223
PRE
Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2023-02-0125
OAAI
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
2023-02-0133
OAAI